Halofuginone hydrobromide, the active substance corresponding to the reference trade product Stenorol, is a synthetic quinazolinone derivative used in veterinary antiprotozoal formulations. The hydrobromide salt is identified by CAS 64924-67-0 and molecular formula C₁₆H₁₈Br₂ClN₃O₃; the free base CAS is 55837-20-2, and the lactate salt used in certain oral solutions is a separate chemical entity with distinct solubility and stability characteristics. The veterinary-grade API is handled as a low-dose active substance because finished feed premixes and oral solutions are prepared in the ppm concentration range; direct addition of neat API to final feed is not acceptable. Release specifications are established through the vendor certificate of analysis and typically address appearance, infrared identity, assay by high-performance liquid chromatography, related substances, residual solvents under VICH GL18, heavy metals by Ph. Eur. 2.4.8, loss on drying, and residue on ignition. The API is supplied in opaque double-lined HDPE containers with desiccant where climatic transport conditions require moisture protection.

What Limits Low-Dose Homogeneity in Veterinary Premix Manufacture?

The principal process constraint is the 1:1000 to 1:10 000 dilution range required to convert a pure API into a feed premix that can be uniformly distributed. A validated intermediate premix step is mandatory; a geometric dilution sequence using a carrier such as calcium carbonate or spray-dried lactose reduces finished-feed coefficient of variation below 5% when sampled according to ISO 6497. Equipment qualification on a ribbon blender or V-blender must include sampling at not fewer than 10 positions after the calculated bulk mixing time; radial and axial segregation can be detected only by lot-specific blend uniformity data. In production-scale ribbon blenders, carryover in dead zones and discharge chutes must be managed by cleaning validation because even 0.1% retained residue can exceed the target low-ppm dosage in the next batch. A pre-blend containing 5–20 g/kg active ingredient is usually prepared with a forced-addition intensifier bar when API lumps are observed.

For granules, wet granulation with purified water or a low-viscosity HPMC binder improves drug distribution and reduces dust generation. A high-shear mixer followed by fluid-bed drying at inlet air temperature not exceeding 50 °C is preferred when forced-degradation data show thermal sensitivity. The granule endpoint is controlled by moisture content, typically below 2.0% after drying, and by sieve retention on a 250 µm screen. If roller compaction is used instead of wet granulation, ribbon solid fraction and granule friability are controlled to avoid excessive fines; published data for this specific formulation configuration is limited, so pilot-scale trials are required before production release.

Tablet manufacture is constrained by the very low dose per unit. Direct compression is feasible only when a geometrically diluted premix is prepared with microcrystalline cellulose, pregelatinised starch, and croscarmellose sodium. A force feeder on a rotary press running at intermediate speed is usually required; the precompression force and main compression force should be selected to produce tablet hardness of 40–80 N, but published data for this specific formulation configuration is limited. Tablet content uniformity should comply with Ph. Eur. 2.9.40, with an acceptance value not exceeding 15.0. Capsule filling on a dosator machine requires relative humidity between 35% and 45% to control static charge and powder flow; HPMC capsule shells may require lower fill speeds than gelatin shells because of their lower moisture content.

Salt-Form Boundaries and Aqueous Processing Envelopes

The hydrobromide salt is preferred for non-aqueous solid premix, powder, granule, and tablet operations because its crystalline habit and salt stoichiometry are more readily controlled during milling. In aqueous systems, however, the solubility of the protonated piperidine form is pH-dependent; an oral solution or injection prepared from the hydrobromide may require acidification below pH 3.0 to retain the active substance in solution, while the free base can precipitate when the pH is raised above 5.5 depending on co-solvent and temperature. For neutral-pH oral solutions, halofuginone lactate is generally the more appropriate salt because it provides higher water solubility. If an injectable presentation is compounded, the formulation must meet sterility requirements and endotoxin limits appropriate to the route; terminal steam sterilisation at 121 °C for 15 min should not be assumed compatible unless aqueous forced-degradation data are available, and sterilising filtration through a 0.22 µm PVDF membrane is often evaluated first. Injectable use of halofuginone is not a standard approved route for poultry coccidiosis in all territories; any investigational or extra-label injectable application requires veterinary oversight.

Powder and solution forms intended for oral administration are commonly packaged in unit-dose sachets or graduated high-density polyethylene bottles with desiccant and child-resistant closures. For oral solutions, a preservative system must be selected after challenge testing under Ph. Eur. 5.1.3; benzalkonium chloride and sodium benzoate are common but require compatibility screening because halofuginone is a cationic amine and can interact with anionic excipients. The use of a co-solvent such as propylene glycol should be justified by solubility data and residue screening because the vehicle can alter the apparent solubility of the free base.

When Ionophore-Based Coccidiostat Programs Are Replaced

In rotation or shuttle programs, replacing monensin, salinomycin, or narasin with halofuginone changes the compatibility envelope with mineral premixes. Polyether ionophores complex with calcium and magnesium; halofuginone does not rely on ion transport across the parasite membrane and therefore does not exhibit the same cation-dependent antagonism. Consequently, separate production lines or documented wall flush cycles may not be required for mineral cross-contamination, but they remain necessary to prevent low-level carryover of the ionophore itself. Published field-resistance data indicate that continuous use of halofuginone can select for reduced susceptibility in Eimeria field isolates; the product should be rotated with a compound from a different chemical class or with a live anticoccidial vaccine according to regional veterinary prescribing. The manufacturing change also requires updating the withdrawal period and residue control plan because halofuginone residue methods differ from ionophore residue methods.

For feed mill operators, a switch to halofuginone requires attention to analytical detection limits. The active substance may be present at final feed concentrations far lower than ionophores; therefore the routine liquid chromatography-mass spectrometry method should be validated for a limit of quantification below 1 ppm in finished feed. Carryover studies should include sampling of the mixer, bucket elevator, pellet mill conditioner, and cooler because residual coccidiostat in press lubrication or steam lines can cause analytical interference. Pellet stability must also be verified; the heat and moisture input in conditioning can reduce assay unless a stabilised granule or protected premix is used.

Particle size distribution of the API can be controlled by air-jet milling to a D90 in the 10–50 µm range for solid dosage forms, or finer if dissolution-limited behaviour is observed in an aqueous suspension. Milling energy can create amorphous domains; X-ray powder diffraction per Ph. Eur. 2.9.33 should confirm crystallinity because amorphous halofuginone is more hygroscopic and can reduce chemical stability. Incoming particle size and bulk density should be trended across batches because shifts in these parameters can alter blend uniformity on production-scale ribbon blenders and rotary tablet presses.

Stability Data Control the Permitted Shelf Life of Low-ppm Premixes

The quinazolinone ring and the brominated aromatic system are potentially sensitive to light and hydrolytic degradation; photostability testing under VICH GL5 is therefore recommended when packaging does not provide a complete light barrier. The bulk API and intermediate premix should be stored below 25 °C in opaque containers, and relative humidity above 60% should be avoided because moisture uptake can accelerate hydrolysis and reduce assay in multi-component premixes. Oxidative degradation can be controlled by minimising headspace oxygen; aluminium foil induction seals are common for high-barrier sachets. The shelf life assigned to the final premix must be justified by long-term data at 25 °C/60% RH or 30 °C/65% RH, depending on the climatic zone, and by accelerated studies at 40 °C/75% RH for not less than 6 months when regulatory submission is required. For tropical distribution, published data for this specific configuration may be limited, and reduced shelf life or refrigerated transport is normally considered.

For medicated feed premixes, the final blending step should be validated under actual production conditions using a tracer-based or assay-based study with at least 10 sampling points, including discharge points. The validation batch record should include mixer load, mixing time, agitator speed, and residual moisture. If the API is milled to reduce particle size, the milled lot should be re-assayed for particle size distribution by laser diffraction per ISO 13320:2020 and for assay because milling can generate amorphous content and reduce crystallinity. Cleaning validation for dry powder lines should use swab limits derived from a maximum allowable carryover of 0.1% of the lowest therapeutic dose in the next product; equipment surfaces of polished stainless steel with a roughness average below 0.8 µm are recommended to minimise API adhesion. Aqueous cleaning of premix lines should be followed by drying to ≤ 0.5% residual moisture before reuse to prevent hydrolysis of residual halofuginone in subsequent batches.